CNB0.F FORTRESS BIOTECH.PRF.A 25
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- 133.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CNB0.F undervalued?
Graham numberThe Graham number of FORTRESS BIOTECH.PRF.A 25 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
FORTRESS BIOTECH.PRF.A 25 fundamental analysis
No fundamental analysis for FORTRESS BIOTECH.PRF.A 25 yet.
FORTRESS BIOTECH.PRF.A 25 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About FORTRESS BIOTECH.PRF.A 25
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of les…
Full company profileFORTRESS BIOTECH.PRF.A 25 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
FORTRESS BIOTECH.PRF.A 25 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 68.8M | 75.7M | 84.5M | 57.7M | 63.3M | 69.5M |
| Gross Profit | 36.7M | 45.0M | 61.6M | 36.8M | 42.3M | 44.8M |
| Operating Income | -179M | -204M | -139M | -111M | -70.2M | -35.5M |
| EBITDA | - | -194M | -136M | -104M | -20.2M | 297M |
| Net Income | -64.7M | -86.6M | -60.6M | -46.0M | 6.82M | 220M |
| EPS | -9.57 | -12 | -4.02 | -1.65 | 0.22 | 6.60 |
| Balance Sheet | ||||||
| Total Assets | 397M | 294M | 168M | 144M | 186M | 317M |
| Total Liabilities | 171M | 244M | 166M | 146M | 123M | 111M |
| Shareholders' Equity | 109M | 41.7M | 22.5M | 22.7M | 49.9M | 164M |
| Cash & Short-term Investments | 306M | 178M | 80.9M | 57.3M | 79.4M | 197M |
| Cash Flow | ||||||
| Operating Cash Flow | -117M | -179M | -128M | -80.2M | -65.8M | 289M |
| Capital Expenditure | 16.3M | 3.06M | 8.10M | 15.0M | 0.00 | 0.00 |
| Free Cash Flow | -133M | -182M | -136M | -95.2M | -65.8M | 289M |
| Ratios | ||||||
| ROE | -59.5% | -207.5% | -269.0% | -202.3% | 13.7% | 133.9% |
| ROA | -16.3% | -29.4% | -36.2% | -31.9% | 3.7% | 69.4% |
| Net Profit Margin | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% | 316.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
FORTRESS BIOTECH.PRF.A 25 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 9.7%
- Ex-dividend date
- Jun 14, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 664K | 0.02 | 9.7% |
| 2024 | USD 4.71M | 0.17 | - |
| 2023 | USD 8.77M | 0.58 | - |
| 2022 | USD 8.78M | 1.19 | - |
| 2021 | USD 8.78M | 1.30 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns FORTRESS BIOTECH.PRF.A 25
Ownership data of FORTRESS BIOTECH.PRF.A 25 is not available yet.
FORTRESS BIOTECH.PRF.A 25 company profile
- Company name
- FORTRESS BIOTECH.PRF.A 25
- Ticker
- CNB0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 78
- Fiscal year end
- December
- Address
- 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
- Phone
- 781 652 4500
- Website
- fortressbiotech.com
About FORTRESS BIOTECH.PRF.A 25
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
FORTRESS BIOTECH.PRF.A 25 management
4- Dr. Lindsay Allan Rosenwald M.D.Executive Chairman, President & CEO · born 1955
- Mr. David JinCFO & Head of Corporate Development · born 1990
- Dr. Xiaoqin Lu M.D.Chief Strategy Officer · born 1975
- Mr. Michael S. Weiss Esq., J.D.Executive Vice Chairman of Strategic Development & Director · born 1966